Stock Quote
NASDAQCRIS

Investor Relations

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers.  The Company currently has three drug candidates in development:

>         Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.

>         CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.

>         CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma.

Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.

The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge(R)  (vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC.

Press Releases
Nov 20, 2018

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster...

Nov 7, 2018

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced upcoming presentations...

View all press releases >>

Events & Presentations
Thursday, November 1, 2018
8:30am - 9:30am EDT
Tuesday, October 2, 2018
5:10pm EDT

View all events & presentations >>

Contact IR

Curis, Inc.
4 Maguire Road

Lexington, MA 02421
Phone: 617-503-6500
Email: info@curis.com

Transfer Agent

Computershare
250 Royall Street
Canton, MA 02021
URL: www.computershare.com/investor
Phone: 877-810-2248

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.